64th ASH Annual Meeting and Exposition: 627. Aggressive Lymphomas: Clinical and Epidemiological: Prognostication and Risk Stratification of Aggressive B-cell NHL

Symposia: Aggressive Lymphomas: Clinical and Epidemiological Oral and Poster Abstracts
Oral

Research, adult, Biological therapies, Antibody Therapy, clinical trials, epidemiology, Lymphomas, non-Hodgkin lymphoma, elderly, Non-Biological therapies, Clinical Practice (Health Services and Quality), Translational Research, Clinical Research, B Cell lymphoma, Chemotherapy, bioinformatics, Combination therapy, health outcomes research, Diseases, real-world evidence, aggressive lymphoma, Therapies, Immunotherapy, therapy sequence, Lymphoid Malignancies, computational biology, Monoclonal Antibody Therapy, Technology and Procedures, Study Population, Human, profiling, imaging, Minimal Residual Disease , omics technologies

New Orleans Theater AB (Ernest N. Morial Convention Center)

Moderators:

P-O Andersson, MD, PhD, Sahlgrenska University Hospital and Emily C. Ayers, MD, University of Virginia

Disclosures:

Andersson: AbbVie: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; AstraZeneca: Speakers Bureau; Beigene: Consultancy, Membership on an entity's Board of Directors or advisory committees; Gilead: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Janssen: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Roche: Speakers Bureau; Sandoz: Consultancy, Membership on an entity's Board of Directors or advisory committees; Takeda: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau.

This session will provide data on the use of various modalities such radiomics, laboratory values, circulating DNA, and geriatric assessment to better determine prognosis and risk stratify patients with aggressive B-cell NHL.

4:00 PM

319

External Validation Shows That Baseline PET Radiomics Outperform the IPI Risk Score for Prediction of Outcome in DLBCL

Jakoba J Eertink, MSc^1,2^*, Gerben JC Zwezerijnen, MD³^*, Martijn W Heymans, PhD⁴^*, Simone Pieplenbosch, MSc⁵^*, Sanne E Wiegers, MSc¹^*, Ulrich Dührsen, Prof, MD, PhD⁶^*, Andreas Hüttmann, MD⁷, Lars Kurch, MD⁸^*, Christine Hanoun⁶^*, Pieternella Lugtenburg, MD, PhD⁹, Sally F Barrington, Prof, MD, PhD¹⁰^*, George Mikhaeel, Prof, MD, PhD¹¹^*, Luca Ceriani, MD¹²^*, Emanuele Zucca, MD¹³, Sandor Czibor¹⁴^*, Tamás Györke, MD, PhD¹⁴^*, Martine E.D. Chamuleau, MD, PhD¹⁵, Otto S Hoekstra, Prof, MD, PhD⁵^*, Henrica C.W de Vet, Prof, PhD⁴^*, Ronald Boellaard, PhD³^* and Josée M. Zijlstra, MD PhD¹

¹Department of Hematology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, the Netherlands, Amsterdam, Netherlands
²on behalf of the PETRA consortium, Amsterdam, Netherlands
³Department of Radiology and Nuclear Medicine, Amsterdam UMC, Location VUmc, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, Netherlands
⁴Department of Epidemiology and Biostatistics, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Public Health research institute, Amsterdam, Netherlands
⁵Amsterdam UMC, Vrije Universiteit Amsterdam, department of Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam, Netherlands
⁶Department of Hematology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
⁷Department of Hematology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, NRW, Germany
⁸Klinik und Poliklinik für Nuklearmedizin, Universitätsklinikum Leipzig, Leipzig, Germany, Leipzig, Germany
⁹Department of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, Netherlands
¹⁰School of Biomedical Engineering and Imaging Sciences, King’s College London and Guys’ & St Thomas PET Imaging Centre, London, Kent, United Kingdom
¹¹Department of Clinical Oncology, Guy’s and St Thomas’ NHS Foundation Trust and Cancer Division, Kings College London, London, United Kingdom
¹²Nuclear Medicine and PET-CT Centre, Imaging Institute of Southern Switzerland, Lugano, Switzerland
¹³IOSI-Oncology Inst. of Southern Switzerland, Bellinzona, Switzerland
¹⁴Department of Nuclear Medicine, Semmelweis University, Budapest, Hungary
¹⁵Amsterdam UMC, Vrije Universiteit Amsterdam, department of Hematology, Cancer Center Amsterdam, Amsterdam, Netherlands

4:15 PM

320

Laboratory Prognostic Index (LaPI) in Diffuse Large B Cell Lymphoma: Validation Study on Behalf of the Spanish Lymphoma Cooperative Group (GEL-TAMO)

Fernando Martín Moro^1,2^*, Leyre Bento De Miguel³^*, Juan Marquet Palomanes, MD⁴^*, Antonio Gutierrez, MD, PhD⁵^*, Antonio Diaz-Lopez, MD⁶^*, Jose M. Sanchez, MD⁷^*, Jose Antonio Garcia Vela, MD⁸^*, Antonio Salar, MD, PhD⁹^*, Raul Cordoba, MD, PhD¹⁰, Silvana Novelli, MD, PhD¹¹, Maria J. Rodriguez-Salazar, MD¹²^*, Sonia González de Villambrosia, MD¹³^*, Raquel Del Campo, MD¹⁴^*, Hugo Daniel Luzardo Henriquez¹⁵^*, Daniel Garcia¹⁶^*, Juan-Manuel Sancho, MD, PhD¹⁷^*, Pau Abrisqueta, MD, PhD¹⁸^*, Alejandro Martín García-Sancho, MD, PhD¹⁹^*, Javier Lopez Jimenez, MD, PhD²⁰^* and Mariana Bastos-Oreiro, MD, PhD²¹^*

¹Hospital Universitario Ramón y Cajal, Madrid, Spain
²University of Alcalá, Alcalá de Henares, Spain
³Department of Hematology, Hospital Universitari Son Espases / IdISBa, Palma, Spain
⁴Hematology Service, Hospital Universitario Ramón y Cajal, Madrid, Spain
⁵Hematology Department, Hospital Universitario Son Dureta, Palma, Spain
⁶Hematology Department, MD Anderson Cancer Center Madrid, Madrid, Spain
⁷Department of Hematology, Hospital Universitario 12 de Octubre, Madrid, ESP
⁸Hematology Department, Hospital Universitario de Getafe, Madrid, Spain
⁹Hematology Department, Hospital del Mar, Barcelona, Spain
¹⁰Department of Hematology, Health Research Institute IIS-FJD, Fundacion Jimenez Diaz University Hospital, Madrid, Spain
¹¹Department of Hematology, Hospital de la Santa Creu I Sant Pau, Barcelona, Spain
¹²Hematology Department, Hospital General Universitario de Canarias, Santa Cruz de Tenerife, Spain
¹³Hematology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain
¹⁴Hospital de Son Llàtzer, Palma, Spain
¹⁵Hospiral Doctor Negrín, Las Palmas de Gran Canaria, Spain
¹⁶Hematology Department, Hospital Sanitas La Zarzuela, Madrid, Spain
¹⁷Clinical Hematology Department, Hospital Germans Trias i Pujol, Badalona, Spain
¹⁸Department of Hematology, Vall d’Hebron University Hospital, Barcelona, Spain
¹⁹Department of Hematology, Hospital Clínico Universitario de Salamanca, IBSAL, Salamanca, Spain
²⁰University Hospital Ramon y Cajal, Madrid, Spain
²¹Servicio de Hematología y Hemoterapia, Hospital Gral. Univ. Gregorio Marañón, Madrid, Madrid, Spain

4:30 PM

321

Novel Simple Prognostic Index (NJHSG-PI) Can Effectively Predict Prognosis in Patients with Newly Diagnosed DLBCL : A Real World Analysis across 14 Cancer Centers in Japan

Koh Izumiyama^1,2^*, Shinpei Harada^2,3^*, Hajime Senjo, M.D.^2,4, Reiki Ogasawara, MD, PhD^2,5^*, Tomoyuki Saga, M.D.^2,6^*, Tetsuyuki Igarashi, M.D.^2,7^*, Kentaro Wakasa, M.D., Ph.D.^2,8^*, Ikumi Kasahara, M.D.^2,9^*, Yukari Takeda, M.D., Ph.D.^2,10^*, Keisuke Yamaguchi, M.D., Ph.D.^2,11^*, Akio Shigematsu, M.D., Ph.D.^2,12, Mutsumi Takahata, M.D., Ph.D.^2,13^*, Katsuya Fujimoto, M.D., Ph.D.^2,14^*, Yoshihito Haseyama, M.D, Ph.D.^2,10^*, Takahiro Nagashima, M.D., Ph.D.^2,15^*, Hajime Sakai, M.D, Ph.D.^2,11, Yasutaka Kakinoki, M.D., Ph.D.^2,16^*, Mitsutoshi Kurosawa, MD, PhD^2,14^* and Takanori Teshima, M.D., Ph.D.^2,4

¹Blood Disorders Center, Aiiku Hospital, Sapporo, Japan
²North Japan Hematolgy Study Group (NJHSG), Sapporo, Japan
³Department of Hematology, Hokkaido University Faculty of Medicine, Sapporo City, Japan
⁴Department of Hematology, Hokkaido University Faculty of Medicine, Sapporo, Japan
⁵Sapporo Hokuyu Hospital, Sapporo, Japan
⁶Department of Hematology, Kin-ikyo Chuo Hospital, Sapporo, Japan
⁷Department of Hematology, Tenshi Hospital, Sapporo, HOK, Japan
⁸Division of Hematology, Hokkaido P.W.F.A.C. Obihiro-Kosei General Hospital, Obihiro, Japan
⁹Sapporo City General Hospital, Sappporo, JPN
¹⁰Department of Hematology, Tonan Hospital, Sapporo, Japan
¹¹Department of Hematology, Teine Keijinkai Hospital, Sapporo, Japan
¹²Department of Hematology, Kushiro Rosai Hospital, Kushiro, Japan
¹³Department of hematology, Sapporo-Kosei General Hospital, Sapporo, Japan
¹⁴Department of Hematology, National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan
¹⁵Department of Internal Medicine, Kitami Red Cross Hospital, Kitami, Japan
¹⁶Department of Hematology, Asahikawa City Hospital, Asahikawa, HOK, Japan

4:45 PM

322

MRD-Negativity As a Potential Surrogate Endpoint after Frontline DLBCL Therapy: Pooled Analysis of Trials & Implications for Clinical Trial Design

Mark Roschewski, MD¹, David M. Kurtz, MD, PhD², Jason Westin, MD³, Ryan C. Lynch, MD⁴, Charles Macaulay, MSc, BA⁵^*, Christian Kuffer⁶^*, Gregory J. Hogan, PhD⁷^*, Sandra Close, PhD⁷^*, Jacob J. Chabon, PhD⁷^*, Davide Rossi, MD, PhD⁸, Maximilian Diehn, MD, PhD⁹^*, Ash A. Alizadeh, MD, PhD¹⁰ and Andre Schultz, PhD⁷^*

¹Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD
²Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA
³Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
⁴Seattle Cancer Care Alliance, Fred Hutchinson Cancer Research Center, Seattle, WA
⁵Department of Medicine, Divisions of Hematology & Oncology, Stanford University Medical Center, Palo Alto, CA
⁶MorphoSys AG, Planegg, Germany
⁷Foresight Diagnostics, Aurora, CO
⁸Institute of Oncology Research, Bellinzona, Switzerland
⁹Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA
¹⁰Divisions of Oncology and Hematology, Department of Medicine, Stanford University School of Medicine, San Mateo, CA

5:00 PM

323

Tafasitamab and Lenalidomide in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL): Real World Outcomes in a Multicenter Retrospective Study

David Qualls, MD¹, Michael J Buege, PharmD², Phuong Dao, PharmD², Paolo F. Caimi, MD³, Sarah C. Rutherford, MD⁴, Graham Wehmeyer, MD⁵^*, Jason T. Romancik, MD⁶, Lori A. Leslie, MD⁷^*, Mwanasha H. Merrill, MD⁸, Jennifer L. Crombie, MD⁹, Behzad Amoozgar, MD, MPH¹⁰^*, Brad S. Kahl, MD¹¹, David A. Bond, MD, BS¹², Kami J. Maddocks, MD¹³, Michelle Okwali, MPH¹^*, Venkatraman Seshan, PhD¹⁴^*, Gilles Salles, MD, PhD¹ and Connie Lee Batlevi, MD, PhD¹⁵

¹Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY
²Department of Pharmacy, Memorial Sloan Kettering Cancer Center, New York, NY
³Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
⁴Meyer Cancer Center, Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY
⁵Department of Medicine, New York-Presbyterian Weill Cornell Medical Center, New York, NY
⁶Department of Hematology and Medical Oncology, Winship Cancer Institute at Emory University, Atlanta, GA
⁷John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ
⁸Dana Farber Cancer Institute, boston, MA
⁹Division of Hematologic Malignancies, Dana Farber Cancer Institute, Boston, MA
¹⁰Department of Medicine, Washington University School of Medicine, St. Louis, MO
¹¹Division of Oncology, Washington University School of Medicine in St. Louis, Saint Louis, MO
¹²Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH
¹³Ohio State University Hospital, Columbus, OH
¹⁴Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY
¹⁵Lymphoma Service, Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, NEW YORK, NY

5:15 PM

324

Incidentally Detected Complex Karyotypic Abnormalities in the Bone Marrow Provide a Clue to Diagnosing Intravascular Large B-Cell Lymphoma

Shinpei Harada¹^*, Hideki Goto, M.D., Ph.D.¹^*, Hajime Senjo, M.D.¹, Keito Suto, M.D.¹^*, Koh Izumiyama²^*, Masayo Yamamoto, M.D., Ph.D.³^*, Kazuya Sato, M.D., Ph.D.⁴, Yasutaka Kakinoki, M.D., Ph.D.⁵^*, Tomoyuki Saga, M.D.⁶^*, Akio Shigematsu, M.D., Ph.D.⁷, Hiroto Horiguchi, MD, PhD⁸, Mutsumi Takahata, M.D., Ph.D.⁹^*, Reiki Ogasawara, M.D., Ph.D.¹⁰^*, Satoshi Yamamoto, M.D., Ph.D.¹¹^*, Keisuke Yamaguchi, M.D., Ph.D.¹²^*, Kentaro Wakasa, M.D., Ph.D.¹³^*, Tetsuyuki Igarashi, M.D.¹⁴^*, Yoshihito Haseyama, M.D, Ph.D.¹⁵^*, Shinichi Ito, M.D.¹⁶^*, Katsuya Fujimoto, M.D., Ph.D.¹⁷^*, Junichi Hashiguchi, M.D., Ph.D.¹⁸^*, Masao Nakagawa, M.D., Ph.D.¹ and Takanori Teshima, M.D., Ph.D.¹

¹Department of Hematology, Hokkaido University Faculty of Medicine, Sapporo, Japan
²Blood Disorders Center, Aiiku Hospital, Sapporo, Japan
³Division of Metabolism and Biosystemic Science, Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, Asahikawa, Japan
⁴Department of Hematology/Oncology, Asahikawa Kosei General Hospital, Asahikawa, Japan
⁵Department of Hematology, Asahikawa City Hospital, Asahikawa, HOK, Japan
⁶Department of Hematology, Kin-ikyo Chuo Hospital, Sapporo, Japan
⁷Department of Hematology, Kushiro Rosai Hospital, Kushiro, Japan
⁸Department of Hematology, Sapporo Medical University School of Medicine, Sapporo, Japan
⁹Department of hematology, Sapporo-Kosei General Hospital, Sapporo, Japan
¹⁰Department of Hematology, Sapporo Hokuyu Hospital, Sapporo, Japan
¹¹Department of Hematology, Sapporo City General Hospital, Sapporo, Japan
¹²Department of Hematology, Teine Keijinkai Hospital, Sapporo, Japan
¹³Division of Hematology, Hokkaido P.W.F.A.C. Obihiro-Kosei General Hospital, Obihiro, Japan
¹⁴Department of Hematology, Tenshi Hospital, Sapporo, HOK, Japan
¹⁵Department of Hematology, Tonan Hospital, Sapporo, Japan
¹⁶Department of Hematology, Hakodate Municipal Hospital, Hakodate, Japan
¹⁷Department of Hematology, National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan
¹⁸Department of Hematology, Kitami Red Cross Hospital, Kitami, Japan

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

627A.O1.6 627. Aggressive Lymphomas: Clinical and Epidemiological: Prognostication and Risk Stratification of Aggressive B-cell NHL